» Articles » PMID: 20346530

In Vivo Silencing of Reptin Blocks the Progression of Human Hepatocellular Carcinoma in Xenografts and is Associated with Replicative Senescence

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2010 Mar 30
PMID 20346530
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: We previously showed that Reptin is overexpressed in hepatocellular carcinoma (HCC), and that in vitro depletion of Reptin with siRNAs led to HCC cell growth arrest and apoptosis. Here, we asked whether in vivo targeting of Reptin in established tumours had a therapeutic effect.

Methods: We used lentiviral vectors to construct HuH7 and Hep3B cell lines with doxycycline (Dox)-dependent expression of Reptin (R2) or control shRNA (GL2). Cells were injected subcutaneously into immunodeficient mice, and Dox was given when tumours reached a volume of 250 mm(3).

Results: In vitro, the growth of GL2-Dox, GL2+Dox, and R2-Dox cells was undistinguishable whereas that of R2+Dox cells stopped 4 days after Dox treatment. The growth decrease was associated with increased apoptosis, and evidence of replicative senescence, as shown by staining for acid beta-galactosidase and the presence of senescence-associated heterochromatin foci. In xenografted mice, R2+Dox tumour growth stagnated or even regressed with prolonged treatment in contrast with the GL2-Dox, GL2+Dox, and R2-Dox tumours that progressed steadily. The blockage of tumour progression was associated with the induction of senescence and reduced cell proliferation.

Conclusions: In vivo Reptin depletion leads to tumour growth arrest. Reptin may prove a valuable target in HCC.

Citing Articles

Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma.

Yi W, Dziadowicz S, Mangano R, Wang L, McBee J, Frisch S Int J Mol Sci. 2024; 25(16).

PMID: 39201707 PMC: 11354775. DOI: 10.3390/ijms25169022.


A Systematic Analysis Reveals the Prognostic and Immunological Role of Reptin/RUVBL2 in Human Tumors.

Su X, Zheng G, Gui Z, Yang X, Zhang L, Pan F Front Genet. 2022; 13:911223.

PMID: 35754815 PMC: 9213802. DOI: 10.3389/fgene.2022.911223.


MTBP and MYC: A Dynamic Duo in Proliferation, Cancer, and Aging.

Grieb B, Eischen C Biology (Basel). 2022; 11(6).

PMID: 35741402 PMC: 9219613. DOI: 10.3390/biology11060881.


Discovery of small-molecule inhibitors of RUVBL1/2 ATPase.

Zhang G, Wang F, Li S, Cheng K, Zhu Y, Huo R Bioorg Med Chem. 2022; 62:116726.

PMID: 35364523 PMC: 9034851. DOI: 10.1016/j.bmc.2022.116726.


Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments.

Ha N, Lee C Cells. 2020; 9(11).

PMID: 33113804 PMC: 7693003. DOI: 10.3390/cells9112352.